Duchenne Muscular Dystrophy - Market Insight, Epidemiology and Market Forecast - 2028

Duchenne Muscular Dystrophy - Market Insight, Epidemiology and Market Forecast - 2028

  • Pages: 100
  • Geography: Global
  • Delivery Timeline: 7-10 Business Days
  • Publication: Jan, 2019
  • SKU: DIMI0275
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Duchenne Muscular Dystrophy - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Duchenne Muscular Dystrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Duchenne Muscular Dystrophy (DMD) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered

  •  The United States
  •  EU5 (Germany, France, Italy, Spain and the United Kingdom)
  •  Japan

Study Period: 2017-2028
Duchenne Muscular Dystrophy - Disease Understanding
Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness. It is one of nine types of muscular dystrophy.
DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3 and 5. The disease primarily affects boys, but in rare cases it can affect girls. DMD is inherited in an X-linked pattern, because the gene that can carry a DMD-causing mutation is on the X chromosome. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications. DMD is classified as a dystrophinopathy. The dystrophinopathies are a spectrum of muscle diseases, each caused by alterations in the dystrophin gene. The most severe end of the spectrum is known as Duchenne muscular dystrophy lacking completely dystrophin protein.
The DelveInsight Duchenne Muscular Dystrophy (DMD) market report gives a thorough understanding of the Duchenne Muscular Dystrophy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Duchenne Muscular Dystrophy in the US, Europe, and Japan.
Duchenne Muscular Dystrophy Epidemiology
The Duchenne Muscular Dystrophy (DMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by diagnosed prevalent population, age-specific prevalent population, mutation-specific prevalent population and prevalent population of associated comorbidities in Duchenne Muscular Dystrophy.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the prevalent population of Duchenne Muscular Dystrophy (DMD) was estimated to be 31,432 [7MM] in 2018. United States accounts for the highest DMD cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries France had the highest prevalent patient population of Duchenne Muscular Dystrophy, followed by Italy.
Duchenne Muscular Dystrophy Drug Chapters
This segment of the Duchenne Muscular Dystrophy report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Current standard of care includes the use of corticosteroids to prolong ambulation and to delay the onset of secondary complications. Early use of cardioprotective agents, noninvasive positive pressure ventilation, and other supportive strategies has improved the life expectancy and health-related quality of life for many young adults with DMD. Treatments include the standard care for DMD along with the new upcoming therapeutic strategies including Genetic Therapies, Cell therapy using muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and Treatment of secondary cascades. Glucocorticoids, more precisely prednisone and deflazacort, form main drug treatment for DMD. Deflazacort is an oxazoline derivate of prednisone. Deflazacort shows more bone-sparing and carbohydrate-sparing properties with less weight-gain effects and improves strength and function. Therefore, Deflazacort becomes the preferred choice over prednisone due to limited side effects and the beneficial properties of muscle sparing and delayed scoliosis progression. The current US market possess only two approved products namely Emflaza and Exondys 51 commercialized by Marathon Pharmaceuticals/ PTC Therapeutics and Sarepta Therapeutics respectively. The recently approved products are known to capture the current market. Detailed chapters for all of these drugs, along with the upcoming therapies i.e., Golodirsen (SRP-4053, Sarepta Therapeutics), Talditercept alfa (also known as RO 6206, RO 7239361, BMS-986089), Idebenone (also known as Catena; CV-2619; Raxone) by Santhera Pharmaceuticals as well as another promising candidate i.e., Givinostat have been covered in the report.
Duchenne Muscular Dystrophy Market Outlook
The Duchenne Muscular Dystrophy (DMD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Treatments include the standard care for DMD along with the new upcoming therapeutic strategies including Genetic Therapies, Cell therapy using muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and Treatment of secondary cascades. The medical management for Duchenne Muscular Dystrophy (DMD) comprises several aspects such as Cardiac care, Diet, Exercise, Respiratory Care, Braces, Spinal curvatures. The treatment strategy is also encompasses supportive treatment and Psychosocial management. DMD is a multilevel/multisystem disease. The medical care of a patient who has DMD and his family is not complete without support for their psychosocial wellbeing.
According to DelveInsight, the global market of Duchenne Muscular Dystrophy (DMD) was estimated to be USD 1,022 million in 2018. The United States accounts for the largest market size of Duchenne Muscular Dystrophy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, France had the highest market size with 84.15 Million in 2018, while Spain had the lowest market size of Duchenne Muscular Dystrophy (DMD). The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.
Duchenne Muscular Dystrophy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Duchenne Muscular Dystrophy (DMD). Owing to the positive outcomes of the several products during the developmental stage by key players such as Santhera Pharmaceutical, Catabasis Pharmaceuticals, Italfarmaco etc. has a potential to create a significant positive shift in the Duchenne Muscular Dystrophy (DMD) Market Size.
Duchenne Muscular Dystrophy Report Insights

  •  Patient Population
  •  Therapeutic Approaches
  •  Pipeline Analysis
  •  Market Size and Trends
  •  Market Opportunities
  •  Impact of upcoming Therapies


Duchenne Muscular Dystrophy Report Key Strengths

  •  10 Year Forecast
  •  7MM Coverage
  •  Epidemiology Segmentation
  •  Drugs Uptake
  •  Highly Analyzed Market
  •  Key Cross Competition


Duchenne Muscular Dystrophy Report Assessment

  •  Current Treatment Practices
  •  Unmet Needs
  •  Detailed Pipeline Product Profiles
  •  Market Attractiveness
  •  Market Drivers and Barriers

Key Benefits

  •  This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Duchenne Muscular Dystrophy market.
  •  Organize sales and marketing efforts by identifying the best opportunities for Duchenne Muscular Dystrophy market.
  •  To understand the future market competition in the Duchenne Muscular Dystrophy market.

1 Key Insights
2 Duchenne Muscular Dystrophy (DMD) Market Overview at a Glance
2.1 Market Share (%) Distribution of Duchenne Muscular Dystrophy (DMD) in 2017
2.2 Market Share (%) Distribution of Duchenne Muscular Dystrophy (DMD) in 2028
3 Disease Background and Overview: Duchenne Muscular Dystrophy (DMD)
3.1 Introduction
3.2 Clinical Manifestations
3.3 Causes
3.3.1 Occurrence of Duchenne in Family
3.4 Inheritance of DMD
3.4.1 Females and DMD
3.5 Pathophysiology
3.6 Biomarkers
3.6.1 Tissue Composition
3.6.2 Genetic Makers
3.6.3 Proteins
3.6.4 Lipids and Metabolites
3.6.5 MicroRNA
3.7 Diagnosis
3.8 Disease Progression
4 Epidemiology and Patient Population
4.1 Key Findings
4.2 7MM Total Patient Population of Duchenne Muscular Dystrophy (DMD)
4.1 7MM Total Diagnosed Patient Population of Duchenne Muscular Dystrophy (DMD)
5 Country Wise-Epidemiology of Duchenne Muscular Dystrophy (DMD)
5.1 United States
5.1.1 Assumptions and Rationale
5.1.2 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United States
5.1.3 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United States
5.1.4 Age- specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States
5.1.5 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States
5.1.6 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the United States
5.2 EU5 Countries
5.2.1 Assumptions and Rationale
5.3 Germany
5.3.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Germany
5.3.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Germany
5.3.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany
5.3.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany
5.3.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Germany
5.4 France
5.4.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in France
5.4.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in France
5.4.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France
5.4.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France
5.4.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in France
5.5 Italy
5.5.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Italy
5.5.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Italy
5.5.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy
5.5.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy
5.5.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Italy
5.6 Spain
5.6.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Spain
5.6.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Spain
5.6.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain
5.6.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain
5.6.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Spain
5.7 United Kingdom
5.7.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United Kingdom
5.7.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United Kingdom
5.7.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom
5.7.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom
5.7.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the United Kingdom
5.8 Japan
5.8.1 Assumptions and Rationale
5.8.2 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Japan
5.8.3 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Japan
5.8.4 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan
5.8.5 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan
5.8.6 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Japan
6 Treatment
6.1 Standard of care for DMD
6.1.1 Corticosteroids
6.2 Therapeutic Strategies
6.2.1 Genetic Therapies
6.2.2 Cell therapy using muscle precursor cells or stem cells
6.2.3 Membrane stabilization and upregulation of cytoskeletal proteins
6.2.4 Treatment of Secondary Cascades
6.3 Medical Management
6.3.1 Braces, standing frames and wheelchairs
6.3.2 Cardiac Care
6.3.3 Contractures
6.3.4 Diet
6.3.5 Exercise
6.3.6 Physical and occupational therapy
6.3.7 Respiratory Care
6.3.8 Spinal Curvatures
6.4 Supportive treatment for DMD
6.5 Psychosocial management
7 United States Guideline on Duchenne Muscular Dystrophy (DMD)
7.1 Efficacy of corticosteroids with regard to Duchenne muscular dystrophy (DMD) progression
7.1.1 Prednisone
7.1.2 Deflazacort
7.2 Optimal dosing regimen
7.2.1 Prednisone
8 Unmet Needs
9 Marketed Drugs
9.1 Emflaza: Marathon Pharmaceuticals/ PTC Therapeutics
9.1.1 Drug Description
9.1.2 Regulatory Milestones
9.1.3 Other Development Activities
9.1.4 Safety and Efficacy
9.1.5 Product Profile
9.2 Exondys 51: Sarepta Therapeutics
9.2.1 Drug Description
9.2.2 Regulatory Milestones
9.2.3 Other Development Activities
9.2.4 Safety and Efficacy
9.2.5 Product Profile
9.3 Translarna: PTC Therapeutics
9.3.1 Drug Description
9.3.2 Regulatory Milestones
9.3.3 Other Development Activities
9.3.4 Safety and Efficacy
9.3.5 Product Profile
10 Emerging Drugs
10.1 Key Cross Competition (Late-Stage Emerging Drugs)
10.2 Key Cross Competition (Mid-Stage Emerging Drugs)
10.3 Golodirsen: Sarepta Therapeutics
10.3.1 Product Description
10.3.2 Other Development Activities
10.3.3 Clinical Development
10.3.4 Product Profile
10.4 Casimersen: Sarepta Therapeutics
10.4.1 Product Description
10.4.2 Other Development Activities
10.4.3 Clinical Development
10.4.4 Product Profile
10.5 Talditercept alfa: Roche
10.5.1 Product Description
10.5.2 Other Development Activities
10.5.3 Clinical Development
10.5.4 Product Profile
10.6 Idebenone: Santhera Pharmaceuticals
10.6.1 Product Description
10.6.2 Other Development Activities
10.6.3 Clinical Development
10.6.4 Safety and Efficacy
10.6.5 Product Profile
10.7 Givinostat: Italfarmaco
10.7.1 Product Description
10.7.2 Other Development Activities
10.7.3 Clinical Development
10.7.4 Safety and Efficacy
10.7.5 Product Profile
10.8 Edasalonexent: Catabasis Pharmaceuticals
10.8.1 Product Description
10.8.2 Other Development Activities
10.8.3 Clinical Development
10.8.4 Safety and Efficacy
10.8.5 Product Profile
10.9 Viltolarsen: Nippon Shinyaku
10.9.1 Product Description
10.9.2 Other Development Activities
10.9.3 Clinical Development
10.9.4 Safety and Efficacy
10.9.5 Product Profile
10.1 Vamorolone: Santhera Pharmaceuticals
10.10.1 Product Description
10.10.2 Other Development Activities
10.10.3 Clinical Development
10.10.4 Safety and Efficacy
10.10.5 Product Profile
11 Duchenne Muscular Dystrophy (DMD): 7 Major Market Analysis
11.1 Key Findings
11.2 Market Size of Duchenne Muscular Dystrophy (DMD) in 7MM
12 The United States Market Outlook
12.1 United States Market Size
12.1.1 Total Market size of Duchenne Muscular Dystrophy (DMD)
12.1.2 Market Size by Therapies
13 EU-5 Countries: Market Outlook
13.1 Germany
13.1.1 Total Market size of Duchenne Muscular Dystrophy (DMD) in Germany
13.1.2 Market Size by Emerging Therapies
13.2 France
13.2.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
13.2.2 Market Size by Emerging Therapies
13.3 Italy
13.3.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
13.3.2 Market Size by Emerging Therapies
13.4 Spain
13.4.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
13.4.2 Market Size by Emerging Therapies
13.5 United Kingdom
13.5.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
13.5.2 Market Size by Emerging Therapies
14 Japan: Market Outlook
14.1 Japan market Size
14.1.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
14.1.2 Market Size by Emerging Therapies
15 Market Drivers
16 Market Barriers
17 Appendix
17.1 Report Methodology
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Table 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Figure 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 37: Treatable Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 42:7MM- Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 45: United States-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 48: Germany-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 51: France-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 54: Italy-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 57: Spain-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 60:UK-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Duchenne Muscular Dystrophy in USD MM (2016-2028)
Figure 63: Japan-Market Share Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Duchenne Muscular Dystrophy by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 5: Sex- Specific Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 6: Diagnosed Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 7: Treatable Cases of the Duchenne Muscular Dystrophy in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 11: Diagnosed Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 12: Treatable Cases of the Duchenne Muscular Dystrophy in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 14: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 15: Sex- Specific Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 16: Diagnosed Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 17: Treatable Cases of the Duchenne Muscular Dystrophy in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 21: Diagnosed Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 22: Treatable Cases of the Duchenne Muscular Dystrophy in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 26: Diagnosed Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 27: Treatable Cases of the Duchenne Muscular Dystrophy in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 30: Sex- Specific Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 31: Diagnosed Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 32: Treatable Cases of the Duchenne Muscular Dystrophy in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Duchenne Muscular Dystrophy in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Duchenne Muscular Dystrophy in Jap